Pharmaceutical

gvhd-drugs-in-development

Articles

GvHD Drugs Treatment Market Heats Up: 4 Late-Stage Therapies Poised to Redefine the Landscape

Explore More...
chronic-spontaneous-urticaria-csu-treatment

Towards a Promising Future: Unveiling Advancements in Chronic Spontaneous Urticaria (CSU) Treatment

pharma-news-for-sobi-gsk-ultragenyx

Sobi’s GAMIFANT Approved by FDA as First Treatment for Macrophage Activation Syndrome in Still’s Disease; GSK Cuts RTS,S Malaria Vaccine Price for Children in Endemic Regions to Under $5; Schrödinger’s SGR-1505 Receives FDA Fast Track Designation for Relapsed/Refractory Waldenström Macroglobulinemia; Ultragenyx’s GTX-102 Granted FDA Breakthrough Therapy Designation for Angelman Syndrome; Eli Lilly’s AMYVID Label Updated by FDA to Support Alzheimer’s Disease Diagnosis

yeztugo-for-hiv

Gilead YEZTUGO Makes History with First Twice-Yearly HIV Prevention Drug

Revolutionizing Schizophrenia Treatment The Key Players Shaping the Future

Revolutionizing Schizophrenia Treatment: The Key Players Shaping the Future

spinal-cord-injury-treatment-landscape

The Spinal Cord Injury Treatment Landscape: Limited Progress, Immense Potential

pharma-news-for-incyte-gilead-archeus

Incyte’s MONJUVI Combo Approved by FDA for Relapsed/Refractory Follicular Lymphoma; Gilead’s YEZTUGO Becomes First FDA-Approved HIV Prevention with 6-Month Protection; FDA Reviewing Incyte’s OPZELURA for Pediatric Atopic Dermatitis (Ages 2–11); Archeus Technologies Receives FDA Clearance for Prostate Cancer Therapy ART-101; Cycle Pharmaceuticals’ HARLIKU Gets First FDA Approval for Alkaptonuria

How Robots Are Introducing A New Dimension To Healthcare Service Delivery

How Robots Are Introducing A New Dimension To Healthcare Service Delivery

postoperative-pain-management-without-opioids

How Could the Approval of JOURNAVX Accelerate the Non-opioids Drug Approval Momentum in Post-Operative Care?

iga-nephropathy-treatment-landscape

Advancements in IgA Nephropathy (IgAN) Treatment: From Standard-of-care (SoC) to Emerging Therapies

pharma-news-for-celltrion-csl-ocugen

Celltrion Announces FDA Nod for New STEQEYMA Presentation to Broaden Pediatric Use; CSL’s ANDEMBRY Gets FDA Nod as First Factor XIIa Inhibitor for Hereditary Angioedema; Ocugen’s OCU410ST Cleared by FDA to Begin Phase II/III Trial in Stargardt Disease; Milestone Pharmaceuticals Submits FDA Response for CARDAMYST in PSVT; AbbVie’s MAVYRET Approved by FDA as First and Only Therapy for Acute Hepatitis C

igg4-related-disease-treatment-landscape

IgG4-Related Disease: A Niche Autoimmune Disorder with Expanding Drug Development Interest

navigating-the-loss-of-exclusivity

Navigating the Loss of Exclusivity: Big Pharma’s New Playbook

Healthcare-Medical-applications-Apps-benefits-disadvantages-types-future-outlook-growth-key-companies

How Healthcare Apps are Adding New Perspectives to the Healthcare Industry?

pharma-news-for-amylyx-cellectar-merck

Amylyx’s AMX0114 Fast Tracked by FDA for ALS; Cellectar’s Iopofosine I 131 Granted FDA Breakthrough in Waldenstrom Macroglobulinemia; YolTech’s YOLT-101 Clears FDA IND for Familial Hypercholesterolemia; Oncovita’s MVdeltaC Gets FDA Orphan Tag for Pleural Mesothelioma; Merck’s ENFLONSIA Approved for RSV Prevention in Infants

epkinly-approval-for-dlbcl-treatment

Abbvie-Genmab’s EPKINLY/TEPKINLY Performance in DLBCL Treatment: The First CD20XCD3 Bispecific Antibody

bispecific-and-trispecific-antibodies

Bispecific and Trispecific Antibodies: Are They Better Than CAR-Ts?

Subscribe to our Updates

DelveInsight is dedicated to safeguarding your data. We ensure that your information is handled in compliance with relevant data privacy legislation, our internal guidelines, and our privacy policy.

Receive recent Healthcare updates directly in your inbox.

Days
loader